Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BrainCool AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 94.87.
BrainCool AB's Days Inventory for the
three
months ended in Mar. 2026 was 230.39.
BrainCool AB's Days Payable for the
three
months ended in Mar. 2026 was 128.28.
Therefore, BrainCool AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 196.98.
BrainCool AB (OSTO:BRAIN) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
BrainCool AB Cash Conversion Cycle Related Terms
BrainCool AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for BrainCool AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:BRAIN vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, BrainCool AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrainCool AB Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BrainCool AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where BrainCool AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
BrainCool AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrainCool AB (OSTO:BRAIN) has a Cash Conversion Cycle of 196.98 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on BrainCool AB and its competitors.
Is BrainCool AB's Cash Conversion Cycle too high?
BrainCool AB's current Cash Conversion Cycle is 196.98. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.96. BrainCool AB's value of 196.98 is 23.9% above this industry median. Overall, BrainCool AB has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BrainCool AB's Cash Conversion Cycle compare to ABT and SYK?
BrainCool AB's Cash Conversion Cycle of 196.98 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.96. BrainCool AB's value of 196.98 is 23.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.96, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrainCool AB's current Cash Conversion Cycle of 196.98 is 23.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on BrainCool AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrainCool AB's current Cash Conversion Cycle is 196.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrainCool AB stock overvalued right now?
Based on GuruFocus' analysis, BrainCool AB (OSTO:BRAIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr1.29, compared to a current price of kr0.71 — trading 45% below its estimated fair value. The current Cash Conversion Cycle is 196.98 and 23.9% above the Medical Devices & Instruments industry median of 158.96. BrainCool AB's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For BrainCool AB (OSTO:BRAIN), the current Cash Conversion Cycle is 196.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrainCool AB (OSTO:BRAIN) Overvalued in 2026?
Based on GuruFocus' analysis, BrainCool AB stock appears to be undervalued.
The current stock price of kr0.71 is trading 45% below its estimated GF Value™ of kr1.29.
GuruFocus considers BrainCool AB to be Possible Value Trap.
Key valuation signals for OSTO:BRAIN:
Cash Conversion Cycle: 196.98
GF Value™: kr1.29 vs. price of kr0.71 (45% below fair value)
Industry Position: 23.9% above the Medical Devices & Instruments median
No single metric tells the full story. See the OSTO:BRAIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrainCool AB is a medical device company engaged in developing, marketing, and selling medical cooling systems for diseases like stroke, oral mucositis, migraine, and sudden cardiac arrest.
69GF Score
Get the complete analysis for OSTO:BRAIN
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BRAIN has been successfully added to your 
